Paul BALDWIN, B. Pharm, Ph.D., Pharmaceutical Development
Paul Baldwin, a Franco-British industrial pharmacist, is a specialist in pharmaceutical formulation and the management of R&D projects. He has twenty years of experience in the pharmaceutical industry:
From 2016 to 2018, Dr. Paul Baldwin was Interim Chief Pharmacist (Qualified Person) at MSD Animal Health Innovation in Beaucouzé, FR, one of the American group's three pharmaceutical Animal Health R&D sites worldwide. Within the same group he spent ten years as an R&D Project Manager. In this position, he was responsible for leading international and multidisciplinary research teams in the pharmaceutical, preclinical and clinical development of new veterinary drugs. He was involved in or led the registration of four new drugs, and wrote, reviewed or verified more than ten EU / US registration dossiers. Dr. Paul Baldwin was also a galenist for Intervet Pharma R&D for seven years, where he was involved in the formulation, development and registration of several drugs, including sterile drugs. Dr. Baldwin has a strong knowledge of quality assurance systems (Good Manufacturing, Laboratory and Clinical Practicies), regulatory texts (European and American Pharmacopoeias) and pharmaceutical guidelines from the EMA and FDA.
Dr. Baldwin, registrable with the French National Order of Pharmacists, holds a graduate degree in Pharmacy (B.Pharm.) from the University of Nottingham (UK) and holds a PhD in Pharmaceutical Sciences, also from he University of Nottingham (UK).
Carl SIMONSSON, Ph.D., Senior Scientist, Formulation & Analytical Method Development
Dr. Carl Simonsson is a medicinal chemist specialized in development and physicochemical characterization of colloidal drug delivery systems and in the vectorization of drugs. He has 15 years experience from research within the fields of formulation development, bio-pharmacy and immunotoxicology.
Prior to joining Cure’nCaps he was R&D project leader and formulation development manager at Carlina Technologies, a biopharmaceutical company specialized in the development of micro- and nanomedicines. There he managed formulation development projects for clients from the pharmaceutical industry. Before that, he worked at the MINT laboratory (Micro et Nanomédecines Translationnelles, INSERM 1066) at the University of Angers on nanomedicine related research projects. Carl Simonsson has a PhD in Medicinal Chemistry form the University of Gothenburg.